Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Memantine add-on to Risperidone in Chronic Schizophrenia
NCT00148616Phase 3Terminated
- Start
- Apr 2004
- Primary completion
- Jun 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in schizophrenia comparing Memantine plus Risperidone with Placebo plus Risperidone (2 arms). Primary endpoint: Positive and Negative Syndrome Scale negative subscore at 24 weeks. Started Apr 2004; status: terminated.
02
Drugs
memantine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT00148616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00148616.